Targeted metabolomic approach in men with carotid plaque

PLoS One. 2018 Jul 16;13(7):e0200547. doi: 10.1371/journal.pone.0200547. eCollection 2018.

Abstract

Background: The aim of the study was to analyse the presence of several metabolites related to atherosclerosis in the plasma of patients with unstable carotid plaque and in the plasma of healthy subjects.

Materials and methods: We included 20 patients who had undergone carotid endarterectomy and 20 healthy subjects as a control group. All the subjects recruited were male. We used a metabolomic approach with liquid chromatography coupled to mass spectrometry to evaluate plasma metabolite levels in the metabolic pathway involved in the progression of atherosclerotic plaque.

Results: We observed that circulating levels of 20-HETE were significantly higher in patients with atheroma plaque than in healthy subjects (p = 0.018). No differences were found with regard to the other metabolites analysed. We also conducted a random forest analysis and found that 20-HETE was the main differentiator in the list of selected metabolites. In addition, plasma levels of 20-HETE correlated positively with body mass index (r = 0.427, p = 0.007) and diastolic blood pressure (r = 0.365, p = 0.028).

Conclusion: This study confirms that of all the molecules studied only 20-HETE is related to carotid plaque. Further studies are needed to compare patients with stable carotid plaque vs. patients with unstable carotid plaque in order to confirm that 20-HETE could be a potential factor related to carotid plaque.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carotid Artery Diseases / blood*
  • Carotid Artery Diseases / surgery
  • Endarterectomy, Carotid
  • Humans
  • Hydroxyeicosatetraenoic Acids / blood*
  • Male
  • Mass Spectrometry*
  • Metabolomics*
  • Middle Aged
  • Plaque, Atherosclerotic / blood*
  • Plaque, Atherosclerotic / surgery

Substances

  • Hydroxyeicosatetraenoic Acids
  • 20-hydroxy-5,8,11,14-eicosatetraenoic acid

Grants and funding

This study was supported by the Fondo de Investigación Sanitaria FEDER (grant number PI16/00498, to T.A.), the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR 2009 SGR 959 to C.R.), the Grup de Recerca en Medicina Aplicada URV (2016PFR-URV-B2-72 to C.R.) and the Fundación Biociencia.